Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceuticals Co., Ltd.

Jiaqiang Cai

Jingyi Wang

Lichun Wang

Qiang Tian

Shuai Song

Hongmei Song

Hong Zeng

Mingliang Zhao

Yongyong Wu

Hanwen Deng

Guoqing Zhong

Yao Liu

Haitao Huang

Zujian Tang

Rongrong Long

Tongtong Xue

Liang Xiao

Wei Zhong

Tianming Wang

Wei Liu

Xin Zhou

Yuting Tan

Baolei Zhang

Chaolei Wang

Xiaofan Duan

Jing Wang

Ying Wang

Dengnian Liu

Qiang Zhang

Donghai Su

Jinming Liu

Chengxi Yang

Yufeng Liang

Liping Liu

Nan Yu

Hua Deng

Daibiao Xiao

Lei Wu

Yitao Zhang

Yongjia Hao

Ruibin Hu

Hao Hu

Weibiao Han

Youqiang Li

Xing Chen

Guangchao Zhang

Shuangshuang Duan

Wei Yin

Xiaoda Niu

Long Yang

Provided herein are bioactive molecule conjugates, preparation methods and use thereof, particularly bioactive molecule conjugates (such as antibody-drug conjugates and small molecule drug conjugates) obtained by improved coupling of a drug and a targeting moiety, as well as their preparation method and use for the treatment of a disease associated with an abnormal cell activity.

Bioactive molecule conjugate, preparation method and use thereof

The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.

Isoxazole derivative, preparation method therefor, and use thereof

Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.

Tetrahydroisoquinoline derivatives, preparation process and use thereof

Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.

Solid form of dihydropyrimidine compound and preparation method therefor and use thereof

Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like. 

Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof

A pharmaceutical composition comprising a 4'-thionucleoside phosphamide derivative or a pharmaceutically acceptable salt, ester, hydrate, solvate, and isomer thereof, any crystalline form thereof or racemate, metabolite, or a combination of a mixture thereof with other drugs, and a method and use thereof for disease treatment and/or prevention.

Pharmaceutical composition for tumor treatment or prevention, method, and use thereof

Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3&#x3b6; molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Cytotoxin and conjugate, uses of same and preparation method therefor

The present invention relates to compounds represented by formula (I) and formula (II) and a chiral synthesis and chiral isolation method therefor, further relating to a salt and crystal form of the compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the preparation of a medicament used for the treatment of a viral infectious disease such as hepatitis B. 

Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof

The present invention relates to a method for prophylactically treating or treating a viral disease, comprising administering to a subject in need thereof a dihydropyrimidine compound, and the viral diseases include, but are not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).

Dihydropyrimidine compound and preparation method and use thereof

The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with &#x3ba;-opioid receptor. The polyamide compound of the invention has excellent &#x3ba;-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain. The compound of the invention has higher selectivity for a &#x3ba;-opioid receptor, lower addictiveness, improved pharmacokinetic properties, and improved safety (lower toxicity and/or fewer side effects), good patient compliance, and/or lesser propensity for developing tolerance, among other excellent medicinal properties.

Polyamide compound and use thereof

Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.

Nucleoside phosphate compound and preparation method and use thereof

The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).

Growing community of inventors

Chengdu, China

Jiaqiang Cai